Applied Genetic Technologies : AGTC Corporate Presentation

This presentation contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs. Forward-looking statements include statements regarding its proposed Phase 2/3 trial design for XLRP, its anticipated timeline and potential to receive FDA approval to begin the XLRP pivotal trial, the timing for reporting data in its XLRP and ACHM clinical programs, its ability to enroll patients for its clinical trials, the expected costs of its clinical programs and its planned manufacturing activities, regulatory progress, potential growth and market opportunities, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: AGTC cannot predict when or if it will obtain regulatory approval to continue to progress its clinical trials, commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; risks related to the COVID-19 outbreak that may delay clinical trial enrollment; gene therapy is still novel with only a few approved treatments so far; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent periodic reports filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Science

Differentiated With

Demonstrated

Capabilities

Superior pre-clinical data

Robust use of disease- specific animal modeling

Manufacturing XLRP

Unmatched	Best-in-Class
Productivity,	Late-Stage
Scalability & Quality	Asset
10-fold reduction in	Improvements in visual
process residuals and	function sustained for at
10-fold increase in	least six months
productivity	No SAEs across
At commercial scale: 40 L	100-fold dose range
≥ 2000 ophthalmic doses

Diversified

Pipeline

High-Value

Programs

Diversified across

ophthalmology,

neurodegenerative and

otology indications

Foundational data

supports development of next-gen technology concepts